FAQ on Quantum BioPharma Ltd.'s Corporate Update and Strategic Initiatives
Summary
What is Quantum BioPharma Ltd. focused on?
Quantum BioPharma Ltd. is dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders, with drug candidates in various stages of development.
What recent corporate updates has Quantum BioPharma announced?
The company announced the grant of 60,000 restricted share units under its equity incentive plan and the settlement of outstanding debt to arm’s length parties by issuing Class B Shares at a deemed price of US$6.75.
What is Lucid-MS?
Lucid-MS is Quantum BioPharma’s lead compound, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
How is Quantum BioPharma involved with UNBUZZD(TM)?
Quantum BioPharma invented UNBUZZD(TM) and retains ownership of 25.71% of Celly Nutrition Corp., which leads its OTC version, along with royalty payments of 7% of sales until $250 million is reached, then 3% in perpetuity.
Where can I find more information about Quantum BioPharma’s latest news and updates?
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
What does Quantum BioPharma’s subsidiary, FSD Strategic Investments Inc., do?
FSD Strategic Investments Inc., a wholly owned subsidiary of Quantum BioPharma, represents loans secured by residential or commercial property, maintaining a portfolio of strategic investments.
How can I view the full press release of Quantum BioPharma’s corporate update?
To view the full press release, visit https://ibn.fm/7WDeK.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 120721